Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Abstract

Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin, and cytarabine (CIA) in relapsed and refractory AML had shown an overall response rate (ORR) of 48%. To explore this combination further, we conducted a phase II study of (CIA) in patients with newly diagnosed AML ≤60 years. Patients ≥18-60 years with AML and adequate organ function were enrolled. Induction therapy consisted of clofarabine (C) 20 mg m⁻² IV daily (days 1-5), idarubicin (I) 10 mg m⁻² IV daily (days 1-3), and cytarabine (A) 1 g m⁻² IV daily (days 1-5). Patients in remission received up to six consolidation cycles (C 15 mg m⁻² × 3, I 8 mg m⁻² × 2, and A 0.75 g m⁻² × 3). Fifty-seven patients were evaluable. ORR was 79%. With a median follow up of 10.9 months, the median overall survival (OS) was not reached, the median event-free survival (EFS) was 13.5 months. Most toxicities were ≤grade 2. Four week mortality was 2%. In subgroup analysis, patients ≤40 years had better OS (P = 0.04) and EFS (P = 0.04) compared to patients >40 years. Compared to historical patients treated with idarubicin and cyarabine (IA), the OS and EFS were significantly longer for CIA treated patients. In multivariate analysis, CIA retained its favorable impact on OS compared to IA. Thus, CIA is an effective and safe therapy for patients ≤60 years with newly diagnosed AML.

• Authors: Aziz Nazha, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Sangbum Choi, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, Jorge Cortes, Alessandra Ferrajoli, Steve Kornblau, Naval Daver, Naveen Pemmaraju, Michael Andreeff, Zeev Estrov, Min Du, Mark Brandt, Stefan Faderl
• Journal: American journal of hematology (Am J Hematol) Vol. 88 Issue 11 Pg. 961-6 (Nov 2013) ISSN: 1096-8652 [Electronic] United States
• PMID: 23877926 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Wiley Periodicals, Inc.

Chemical References

• Adenine Nucleotides
• Antibiotics, Antineoplastic
• Antimetabolites, Antineoplastic
• Arabinonucleosides
• Cytarabine
• Clofarabine
• Idarubicin

Topics

• Adenine Nucleotides (administration & dosage, adverse effects, therapeutic use)
• Adult
• Age Factors
• Antibiotics, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Antimetabolites, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Arabinonucleosides (administration & dosage, adverse effects, therapeutic use)
• Clofarabine
• Consolidation Chemotherapy (adverse effects)
• Cytarabine (administration & dosage, adverse effects, therapeutic use)
• Drug Eruptions (etiology)
• Follow-Up Studies
• Humans
• Idarubicin (administration & dosage, adverse effects, therapeutic use)
• Induction Chemotherapy (adverse effects)
• Leukemia, Myeloid, Acute (drug therapy)
• Middle Aged
• Nausea (chemically induced)
• Pilot Projects
• Remission Induction
• Survival Analysis
• Young Adult